ImmuPharma PLC (UK) Top Management

ImmuPharma PLC Management Team Effectiveness

The company has return on total asset (ROA) of (0.43) % which means that it has lost $0.43 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.112) %, meaning that it generated substantial loss on money invested by shareholders. ImmuPharma PLC's management efficiency ratios could be used to measure how well ImmuPharma PLC manages its routine affairs as well as how well it operates its assets and liabilities. At present, ImmuPharma PLC's Intangible Assets are projected to decrease significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 5.2 M, whereas Non Current Assets Total are forecasted to decline to about 1.4 M. The current year's Common Stock Shares Outstanding is expected to grow to about 380.1 M, whereas Net Loss is projected to grow to (7 M).

ImmuPharma PLC Workforce Comparison

ImmuPharma PLC Benchmark Summation

ImmuPharma PLC Notable Stakeholders

The success or failure of an entity such as ImmuPharma PLC often depends on how effective the management is. ImmuPharma PLC management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of ImmuPharma management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the ImmuPharma management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the presentation of ImmuPharma PLC's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, ImmuPharma PLC's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of ImmuPharma PLC's management manipulating its earnings.

When running ImmuPharma PLC's price analysis, check to measure ImmuPharma PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImmuPharma PLC is operating at the current time. Most of ImmuPharma PLC's value examination focuses on studying past and present price action to predict the probability of ImmuPharma PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImmuPharma PLC's price. Additionally, you may evaluate how the addition of ImmuPharma PLC to your portfolios can decrease your overall portfolio volatility.